|
1
|
Lau LF and Nathans D: Identification of a
set of genes expressed during the G0/G1 transition of cultured
mouse cells. EMBO J. 4:3145–3151. 1985.PubMed/NCBI
|
|
2
|
Brigstock DR, Goldschmeding R, Katsube KI,
Lam SC, Lau LF, Lyons K, Naus C, Perbal B, Riser B, Takigawa M, et
al: Proposal for a unified CCN nomenclature. Mol Pathol.
56:127–128. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perbal B: CCN proteins: Multifunctional
signalling regulators. Lancet. 363:62–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Brien TP, Yang GP, Sanders L and Lau LF:
Expression of cyr61, a growth factor-inducible immediate-early
gene. Mol Cell Biol. 10:3569–3577. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brunner A, Chinn J, Neubauer M and Purchio
AF: Identification of a gene family regulated by transforming
growth factor-beta. DNA Cell Biol. 10:293–300. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jay P, Bergé-Lefranc JL, Marsollier C,
Méjean C, Taviaux S and Berta P: The human growth factor-inducible
immediate early gene, CYR61, maps to chromosome 1p. Oncogene.
14:1753–1757. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martinerie C, Viegas-Pequignot E, Nguyen
VC and Perbal B: Chromosomal mapping and expression of the human
cyr61 gene in tumour cells from the nervous system. Mol Pathol.
50:310–316. 1997. View Article : Google Scholar
|
|
8
|
Brigstock DR: The CCN family: A new
stimulus package. J Endocrinol. 178:169–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Menéndez JA, Mehmi I, Griggs DW and Lupu
R: The angiogenic factor CYR61 in breast cancer: Molecular
pathology and therapeutic perspectives. Endocr Relat Cancer.
10:141–152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leask A and Abraham DJ: All in the CCN
family: Essential matricellular signaling modulators emerge from
the bunker. J Cell Sci. 119:4803–4810. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tong X, O'Kelly J, Xie D, Mori A, Lemp N,
McKenna R, Miller CW and Koeffler HP: Cyr61 suppresses the growth
of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53
pathway. Oncogene. 23:4847–4855. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim SY, Hahn HG, Nam KD, Park KC, Yun HY,
Baek KJ, Kwon NS and Kim DS: A derivative of 2-aminothiazole
inhibits melanogenesis in B16 mouse melanoma cells via glycogen
synthase kinase 3β phosphorylation. J Pharm Pharmacol.
63:1031–1036. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klebanoff CA, Gattinoni L, Palmer DC,
Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD,
Finkelstein SE, et al: Determinants of successful CD8+
T-cell adoptive immunotherapy for large established tumors in mice.
Clin Cancer Res. 17:5343–5352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao H, Peng Y, Hong Y, Liu Y, Guo ZS,
Bartlett DL, Fu N and He Y: Lentivector prime and vaccinia virus
vector boost generate high-quality CD8 memory T cells and prevent
autochthonous mouse melanoma. J Immunol. 187:1788–1796. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Babic AM, Kireeva ML, Kolesnikova TV and
Lau LF: CYR61, a product of a growth factor-inducible immediate
early gene, promotes angiogenesis and tumor growth. Proc Natl Acad
Sci USA. 95:6355–6360. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kunz M, Moeller S, Koczan D, Lorenz P,
Wenger RH, Glocker MO, Thiesen HJ, Gross G and Ibrahim SM:
Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61
in melanoma cells. J Biol Chem. 278:45651–45660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dobroff AS, Wang H, Melnikova VO, Villares
GJ, Zigler M, Huang L and Bar-Eli M: Silencing cAMP-response
element-binding protein (CREB) identifies CYR61 as a tumor
suppressor gene in melanoma. J Biol Chem. 284:26194–26206. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carmichael J, DeGraff WG, Gazdar AF, Minna
JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: Assessment of radiosensitivity. Cancer Res.
47:943–946. 1987.PubMed/NCBI
|
|
19
|
Alley MC, Scudiero DA, Monks A, Hursey ML,
Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd
MR: Feasibility of drug screening with panels of human tumor cell
lines using a microculture tetrazolium assay. Cancer Res.
48:589–601. 1988.PubMed/NCBI
|
|
20
|
Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He
D, Ouyang G, Lin J, Shen B, Shi Y, et al: A critical role of Cyr61
in interleukin-17-dependent proliferation of fibroblast-like
synoviocytes in rheumatoid arthritis. Arthritis Rheum.
60:3602–3612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun M, Ma F, Zeng X, Liu Q, Zhao XL, Wu
FX, Wu GP, Zhang ZF, Gu B, Zhao YF, et al: Triphalangeal
thumb-polysyndactyly syndrome and syndactyly type IV are caused by
genomic duplications involving the long range, limb-specific SHH
enhancer. J Med Genet. 45:589–595. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin MT, Chang CC, Chen ST, Chang HL, Su
JL, Chau YP and Kuo ML: Cyr61 expression confers resistance to
apoptosis in breast cancer MCF-7 cells by a mechanism of
NF-kappaB-dependent XIAP up-regulation. J Biol Chem.
279:24015–24023. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Menendez JA, Vellon L, Mehmi I, Teng PK,
Griggs DW and Lupu R: A novel CYR61-triggered 'CYR61-alphavbeta3
integrin loop' regulates breast cancer cell survival and
chemosensitivity through activation of ERK1/ERK2 MAPK signaling
pathway. Oncogene. 24:761–779. 2005. View Article : Google Scholar
|
|
24
|
Xie D, Yin D, Wang HJ, Liu GT, Elashoff R,
Black K and Koeffler HP: Levels of expression of CYR61 and CTGF are
prognostic for tumor progression and survival of individuals with
gliomas. Clin Cancer Res. 10:2072–2081. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Holloway SE, Beck AW, Girard L, Jaber MR,
Barnett CC Jr, Brekken RA and Fleming JB: Increased expression of
Cyr61 (CCN1) identified in peritoneal metastases from human
pancreatic cancer. J Am Coll Surg. 200:371–377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tong X, Xie D, O'Kelly J, Miller CW,
Muller-Tidow C and Koeffler HP: Cyr61, a member of CCN family, is a
tumor suppressor in non-small cell lung cancer. J Biol Chem.
276:47709–47714. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sampath D, Zhu Y, Winneker RC and Zhang Z:
Aberrant expression of Cyr61, a member of the CCN
(CTGF/Cyr61/Cef10/NOVH) family, and dysregulation by 17
beta-estradiol and basic fibroblast growth factor in human uterine
leiomyomas. J Clin Endocrinol Metab. 86:1707–1715. 2001.PubMed/NCBI
|
|
28
|
Wasenius VM, Hemmer S, Kettunen E,
Knuutila S, Franssila K and Joensuu H: Hepatocyte growth factor
receptor, matrix metalloproteinase-11, tissue inhibitor of
metalloproteinase-1, and fibronectin are up-regulated in papillary
thyroid carcinoma: A cDNA and tissue microarray study. Clin Cancer
Res. 9:68–75. 2003.PubMed/NCBI
|
|
29
|
Chien W, Kumagai T, Miller CW, Desmond JC,
Frank JM, Said JW and Koeffler HP: Cyr61 suppresses growth of human
endometrial cancer cells. J Biol Chem. 279:53087–53096. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dika E, Fanti PA, Vaccari S, Patrizi A and
Maibach HI: Causal relationship between exposure to chemicals and
malignant melanoma? A review and study proposal. Rev Environ
Health. 25:255–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kong Y, Kumar SM and Xu X: Molecular
pathogenesis of sporadic melanoma and melanoma-initiating cells.
Arch Pathol Lab Med. 134:1740–1749. 2010.PubMed/NCBI
|
|
32
|
Mihić LL, Bulat V, Situm M, Krolo I and
Seserko A: The role of apoptosis in the pathogenesis of malignant
melanoma. Coll Antropol. 34(Suppl 2): 303–306. 2010.
|
|
33
|
Khalid U, Saleem T, Imam AM and Khan MR:
Pathogenesis, diagnosis and management of primary melanoma of the
colon. World J Surg Oncol. 9:142011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gruber F, Kastelan M, Brajac I, Saftić M,
Peharda V, Cabrijan L, Stanić Zgombić Z and Simonić E: Molecular
and genetic mechanisms in melanoma. Coll Antropol. 32(Suppl 2):
147–152. 2008.
|
|
35
|
Ibrahim N and Haluska FG: Molecular
pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol.
4:551–579. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Russo AE, Torrisi E, Bevelacqua Y,
Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and
Malaponte G: Melanoma: Molecular pathogenesis and emerging target
therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI
|
|
37
|
Ugurel S, Utikal J and Becker JC: Tumor
biomarkers in melanoma. Cancer Control. 16:219–224. 2009.PubMed/NCBI
|
|
38
|
Chandeck C and Mooi WJ: Oncogene-induced
cellular senescence. Adv Anat Pathol. 17:42–48. 2010.
|
|
39
|
Parsons BL, Myers MB, Meng F, Wang Y and
McKinzie PB: Oncomutations as biomarkers of cancer risk. Environ
Mol Mutagen. 51:836–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Adhikari AS and Iwakuma T: Mutant p53 gain
of oncogenic function: In vivo evidence, mechanism of action and
its clinical implications. Fukuoka Igaku Zasshi. 100:217–228.
2009.PubMed/NCBI
|
|
41
|
Bar J, Moskovits N and Oren M: Involvement
of stromal p53 in tumor-stroma interactions. Semin Cell Dev Biol.
21:47–54. 2010. View Article : Google Scholar :
|
|
42
|
Lane D and Levine A: p53 Research: The
past thirty years and the next thirty years. Cold Spring Harb
Perspect Biol. 2:a0008932010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Solomon H, Brosh R, Buganim Y and Rotter
V: Inactivation of the p53 tumor suppressor gene and activation of
the Ras oncogene: Cooperative events in tumorigenesis. Discov Med.
9:448–454. 2010.PubMed/NCBI
|
|
44
|
Dervan PA, Magee HM, Buckley C and Carney
DN: Proliferating cell nuclear antigen counts in formalin-fixed
paraffin-embedded tissue correlate with Ki-67 in fresh tissue. Am J
Clin Pathol. 97(Suppl 1): S21–S28. 1992.PubMed/NCBI
|
|
45
|
Bolton WE, Mikulka WR, Healy CG,
Schmittling RJ and Kenyon NS: Expression of proliferation
associated antigens in the cell cycle of synchronized mammalian
cells. Cytometry. 13:117–126. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nakano H, Namatame K, Suzuki T, Takahashi
H, Sakai H, Nakamura T and Kumada K: Histopathological response to
preoperative chemotherapy including 5-fluorouracil additionally
assessed by immunocytochemical and pharmacologic parameters in
patients with advanced gastric cancer. Surg Today. 26:482–488.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hiraga Y, Tanaka S, Haruma K, Yoshihara M,
Sumii K, Kajiyama G, Shimamoto F and Kohno N: Immunoreactive MUC1
expression at the deepest invasive portion correlates with
prognosis of colorectal cancer. Oncology. 55:307–319. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kunihiro M, Tanaka S, Haruma K, Yoshihara
M, Sumii K, Kajiyama G and Shimamoto F: Combined expression of
HLA-DR antigen and proliferating cell nuclear antigen correlate
with colorectal cancer prognosis. Oncology. 55:326–333. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jia X and Han C: Biomarkers in the studies
on chemoprevention of colorectal cancer. Wei Sheng Yan Jiu.
29:109–111. 2000.In Chinese.
|
|
50
|
Reszeć J, Kańczuga-Koda L, Sulkowska M,
Koda M, Cylwik J, Barwijuk-Machała M and Sulkowski S: An evaluation
of Ki-67 and PCNA expression in conjunctival and eyelid tumours.
Folia Morphol (Warsz). 63:95–98. 2004.
|
|
51
|
Meyer O: Interferons and autoimmune
disorders. Joint Bone Spine. 76:464–473. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Heng DY and Bukowski RM: Anti-angiogenic
targets in the treatment of advanced renal cell carcinoma. Curr
Cancer Drug Targets. 8:676–682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Agarwala SS and Case S: Everolimus
(RAD001) in the treatment of advanced renal cell carcinoma: A
review. Oncologist. 15:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ather MH, Masood N and Siddiqui T: Current
management of advanced and metastatic renal cell carcinoma. Urol J.
7:1–9. 2010.PubMed/NCBI
|
|
55
|
Ramakrishna R and Manoharan A: Sustained
long-term remissions with weekly interferon maintenance therapy in
hairy cell leukemia. Asia Pac J Clin Oncol. 6:210–212. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Baldo P, Rupolo M, Compagnoni A, Lazzarini
R, Bearz A, Cannizzaro R, Spazzapan S, Truccolo I and Moja L:
Interferon-alpha for maintenance of follicular lymphoma. Cochrane
Database Syst Rev. CD0046292010.PubMed/NCBI
|
|
57
|
Burchert A and Neubauer A: Interferon
alpha and T-cell responses in chronic myeloid leukemia. Leuk
Lymphoma. 46:167–175. 2005. View Article : Google Scholar
|
|
58
|
Khoo TL, Vangsted AJ, Joshua D and Gibson
J: Interferon-alpha in the treatment of multiple myeloma. Curr Drug
Targets. 12:437–446. 2011. View Article : Google Scholar
|
|
59
|
Garbe C, Eigentler TK, Keilholz U,
Hauschild A and Kirkwood JM: Systematic review of medical treatment
in melanoma: Current status and future prospects. Oncologist.
16:5–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Aversa SM, Cattelan AM, Salvagno L,
Crivellari G, Banna G, Trevenzoli M, Chiarion-Sileni V and
Monfardini S: Treatments of AIDS-related Kaposi's sarcoma. Crit Rev
Oncol Hematol. 53:253–265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chowdhury S, Larkin JM and Gore ME: Recent
advances in the treatment of renal cell carcinoma and the role of
targeted therapies. Eur J Cancer. 44:2152–2161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Massironi S, Sciola V, Peracchi M,
Ciafardini C, Spampatti MP and Conte D: Neuroendocrine tumors of
the gastro-entero-pancreatic system. World J Gastroenterol.
14:5377–5384. 2008. View Article : Google Scholar : PubMed/NCBI
|
